BIVI: Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burdenQuartr·Sep 15 at 02:06 PMBIVI-5.06%
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDUnusual Whales·Sep 15 at 11:32 AMBIVI-5.06%
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid | BIVI Stock NewsStockTitan·Sep 14 at 12:01 PMBIVI-5.06%
BioVie signs at-the-market equity sales agreement for up to $6.46 million Class A sharesPUBT·Sep 14 at 10:02 AMBIVI-5.06%
BioVie seeks FDA end-of-Phase 2 meeting to advance bezisterim Phase 3 Parkinson’s trial designPUBT·Sep 8 at 11:31 AMBIVI-5.06%
BioVie completes treatment phase of Phase 2 Long COVID trial for bezisterimPUBT·Aug 31 at 12:05 PMBIVI-5.06%
Joseph Palumbo Purchases 4,843 Shares of BioVie (NASDAQ:BIVI) StockMarket Beat·Aug 29 at 11:07 AMBIVI-5.06%
